Welcome to our dedicated page for Amarin Plc news (Ticker: AMRN), a resource for investors and traders seeking the latest updates and insights on Amarin Plc stock.
Amarin Corporation Plc (NASDAQ: AMRN) is a pioneering biopharmaceutical company dedicated to improving cardiovascular health through the development and commercialization of innovative therapeutic products. The company's flagship product, VASCEPA® (icosapent ethyl), is designed to address cardiovascular risks and has received FDA approval in the United States as well as marketing authorization in Europe under the brand name VAZKEPA®.
Amarin's mission is to advance scientific understanding and provide effective treatments for high-risk cardiovascular patients who have not adequately responded to traditional therapies. VASCEPA, a unique form of eicosapentaenoic acid (EPA), has been shown in clinical trials to significantly reduce cardiovascular events, offering a new therapeutic option for patients with elevated triglyceride levels.
In recent years, Amarin has undertaken strategic initiatives to bolster its market presence and financial stability. Notable accomplishments include:
- Leadership Restructure: In 2023, Amarin appointed new executives, including President & CEO Patrick Holt, to drive the company's global strategy and operational improvements.
- Revenue Growth in Europe: Amarin reported approximately 65% growth in in-market sales in Europe for Q1 2024 compared to Q4 2023, with significant progress in Spain and the UK.
- Financial Discipline: The company has implemented measures to reduce operating expenses and preserve cash, closing 2023 with $321 million in cash and no debt.
- Share Repurchase Plan: In early 2024, Amarin announced a share repurchase plan of up to $50 million to enhance shareholder value, pending necessary approvals.
Amarin's commitment to cardiovascular health extends globally, with operations in the United States, Europe, and partnerships in Canada, China, and other regions. The company continues to explore new market opportunities and strengthen its intellectual property portfolio, as evidenced by the recent extension of VAZKEPA's patent protection in Europe until 2039.
For more information, visit www.amarincorp.com and the dedicated VASCEPA site at www.vascepa.com.
Amarin Corporation has successfully launched VAZKEPA (icosapent ethyl) in Germany, marking its first entry into the European market. VAZKEPA is designed to reduce cardiovascular risks in statin-treated adults with elevated triglycerides. The drug received approval from the European Commission in March 2021. Backed by over a decade of research, including the REDUCE-IT® study, VAZKEPA is endorsed by key cardiovascular disease treatment guidelines. The launch is a part of Amarin's growth strategy, aiming to address the significant cardiovascular burden in Europe, where CVD is the leading cause of death.
Amarin Corporation plc (NASDAQ: AMRN) announced participation in two upcoming virtual investment conferences in September 2021. The H. C. Wainwright 23rd Annual Global Investment Conference will feature an on-demand presentation available on September 13, 2021, at 7:00 a.m. ET. The Cantor Fitzgerald Global Healthcare Conference 2021 will include a live presentation on September 28, 2021, at 2:40 p.m. ET. Both presentations will be webcast live and archived for 90 days on Amarin's Investor Relations website.
Amarin Corporation (NASDAQ:AMRN) announced significant findings related to VASCEPA/VAZKEPA presented at ESC Congress 2021. The data revealed a 26% reduction in first and 35% reduction in total primary endpoints for patients with a history of myocardial infarction, reinforcing VASCEPA's role in cardiovascular risk reduction. Additionally, VAZKEPA was included in the 2021 ESC Guidelines for patients with elevated triglycerides, marking its 20th recognition in global guidelines. Despite promising findings, the identical PREPARE-IT 1 trial did not meet its primary endpoint.
Amarin Corporation (NASDAQ:AMRN) presented new analyses of VASCEPA® (icosapent ethyl) at ESC Congress 2021, revealing it reduces major adverse cardiovascular events in patients with prior myocardial infarction (MI) by 26% and total primary endpoints by 35%. Conducted as part of the REDUCE-IT study, these findings highlight VASCEPA's importance in cardiovascular risk management. Experts emphasize its efficacy in patients at high risk for recurrent events, further supporting its role as a treatment beyond statins.
Amarin Corporation has announced that new data supporting the efficacy of VASCEPA in preventing major adverse cardiovascular events will be presented at the ESC Congress 2021, taking place from August 27 to August 30, 2021. The presentations will include two Late-Breaking Science sessions and five e-Posters, showcasing research on icosapent ethyl. CEO Karim Mikhail highlighted the upcoming European launch of VASCEPA, starting in Germany, and anticipates results from the PREPARE-IT 1 trial, which investigates VASCEPA's role in COVID-19 prevention.
Amarin Corporation (NASDAQ:AMRN) reported a net revenue of $154.5 million for Q2 2021, marking a 14% increase from the previous year. The company is set to launch its cardiovascular drug VAZKEPA in Germany by September 2021, having filed market access dossiers in multiple European countries with a proposed pricing of approximately €200 per month. Amarin has received marketing authorization in Great Britain and aims for regulatory approval in 20 additional countries. The company ended Q2 with $523.1 million in cash and investments, enhancing its capacity for growth.
Amarin Corporation plc (NASDAQ:AMRN) announced a conference call to discuss its Q2 and H1 2021 financial results on August 5, 2021, at 7:30 a.m. ET. The call will be available on their investor relations website and via telephone. Investors are encouraged to follow the updates on their website for material information concerning Amarin's ongoing developments in cardiovascular disease management.
Amarin Corporation plc (NASDAQ: AMRN) presented new research on icosapent ethyl, marketed as VASCEPA® and VAZKEPA in Europe, at the EAS Congress 2021. The studies reveal multiple mechanisms by which icosapent ethyl impacts cardiovascular health, including its anti-inflammatory properties and protein modulation. Key findings include the modulation of over 50 proteins in endothelial cells after interleukin-6 exposure, reduction of platelet activation proteins, and decreased nitrite production in macrophages. These insights support icosapent ethyl's role in cardiovascular risk reduction.
Amarin Corporation plc (NASDAQ:AMRN) announced upcoming presentations by CEO John F. Thero and Senior VP Karim Mikhail at two key investor conferences in June 2021. The Jefferies Virtual Healthcare Conference will take place on June 2 at 9:30 a.m. ET, followed by the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8 at 10:30 a.m. ET. Live webcasts will be available on Amarin's website for 30 days. Amarin is committed to advancing cardiovascular disease management through innovative research and clinical trials.
Amarin Corporation announced substantial findings regarding VASCEPA® (icosapent ethyl) from the ACC.21 conference. The REDUCE-IT trial showed a 55% reduction in total plaque volume and a 61% reduction in non-calcified plaque volume, indicating significant cardiovascular risk reduction. Analyses confirmed that icosapent ethyl significantly cut ischemic events by 30-40% in dyslipidemic patients. This data emphasizes the efficacy of icosapent ethyl in managing cardiovascular risk, reinforcing its status as the only approved therapy for this purpose in the U.S., Canada, and Europe.
FAQ
What is the current stock price of Amarin Plc (AMRN)?
What is the market cap of Amarin Plc (AMRN)?
What does Amarin Corporation do?
What is VASCEPA®?
How did Amarin perform financially in recent quarters?
What recent strategic initiatives has Amarin undertaken?
What are the key markets for Amarin's products?
What recent achievements have boosted Amarin's market position?
How does VASCEPA® benefit patients?
Who are the key executives at Amarin?
What is the purpose of Amarin's share repurchase plan?
How does Amarin support its global operations?
